Amarin Corp Plc (AMRN)

[sts66]

Erm....because it's a drug? And by FDA/FDCA definitions it cannot be a DS, which is part of their ITC argument. I assume you didn't mean selling it OTC, and answer to that is obvious - cost would be too high and couldn't be offset by insurance - AMRN couldn't have helped fund R-IT if they lowered the price to a point where consumers might actually be willing to pay for it out of pocket. Plus FDA probably wouldn't have agreed to let them sell it OTC w/o any long term safety studies in hand, and they'd have made the right decision given the surprising increase in A-Fib in the V group.